Vol. 23/No. 14 | OncologyLive

New Approvals Help Fill Unmet Need in Treating Chronic GVHD

July 26, 2022

A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.

Immune Checkpoint Inhibitors at ASCO: Long-term Efficacy Data Mount

July 25, 2022

Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.

Is It Time to Formally Recognize That PFS Is More Than a "Surrogate" End Point?

July 18, 2022

Peer-reviewed articles continue to challenge the recognition of progression-free survival as an acceptable primary end point in randomized cancer trials or insist on labeling this objectively measured outcome as nothing more than a potential surrogate for effects representing actual clinically meaningful results.